MAP2K7 and hepatocellular carcinoma: Sorafenib is a well-known drug used to treat HCC in clinics, as a Raf inhibitor, which significantly inhibits the phosphorylation of MEK and ERK, but not the expression of MEK and ERK, and inhibits the AKT signaling pathway.